Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Humana (HUM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Humana (HUM) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Humana (HUM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Humana targets a 3% Medicare Advantage margin by 2028 while pursuing 25% 2026 membership growth and rebuilding profitability despite industry headwinds.
CenterWell's rapid growth is helping HUM expand beyond insurance with integrated care, acquisitions, AI and a 2026 revenue target of at least $25B.
HUM is shifting from membership growth to profitability, with lower medical costs, rising CenterWell revenues, and a margin recovery plan through 2028.
HUM is cashing out its Gentiva stake for $900 million, completing a multiyear effort to sharpen focus on its core health insurance business.
Humana, one of the nation's largest providers of privatized Medicare Advantage health insurance for older adults, announced plans to divest its minority stake in a provider of end-of-life services for $900 million.
Humana said on Wednesday it has agreed to sell all or substantially all of its minority stake in Gentiva, a provider of hospice and palliative care services, in a deal valuing the stake at about $900 million.
Tech stocks are pulling back, and healthcare is surging.
Health insurers are running higher in Thursday afternoon trading after a wave of bullish Wall Street analyst notes on the managed-care sector, centered on UnitedHealth, citing softer medical cost and utilization trends plus potential AI efficiency upside.